Metformin and Galantamine Combination Modestly Improves Sarcopenia Symptoms
Therapies that reuse existing drugs with sizable bodies of human data tend to move more rapidly to the clinic than is the case for better, more ambitious approaches that break new ground. Greater speed in reaching the clinic means a lower cost of development, and this economic incentive is why so much of clinical development consists of drug reuse and only modestly effective therapies. In the case of sarcopenia, the age-related loss of muscle mass and strength, sizable funding is presently devoted to the development of small molecule therapies that do not produce greater gains than resistance exercise. A good deal of what ...
Source: Fight Aging! - March 13, 2024 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, December 25th 2023
This study generates a comprehensive single-cell transcriptomic atlas of human atherosclerosis including 118,578 high-quality cells from atherosclerotic coronary and carotid arteries. By performing systematic benchmarking of integration methods, we mitigated data overcorrection while separating major cell lineages. Notably, we define cell subtypes that have not been previously identified from individual human atherosclerosis scRNA-seq studies.
Besides characterizing granular cell-type diversity and communication, we leverage this atlas to provide insights into smooth muscle cell (SMC) modulation. We integrate genome...
Source: Fight Aging! - December 24, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Existing Geroprotective Drugs May Not Interact Well with Exercise
The big disadvantage of the geroprotective approach to aging, which is essentially to undertake the long-term use of supplements and small molecule drugs to alter metabolism in ways that slow aging over years and decades, is that distinct supplements and small molecules and adjustments tend to combine in unexpected ways. Short of testing every combination in laboratory species, something that Brian Kennedy's team has been working on, one can never know the outcome of combining a treatment. Based on presentations and interviews given by Kennedy in the last few years, the result of combining two geroprotectors that individua...
Source: Fight Aging! - December 21, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Ginger Vieira – Exercise with Type 1 Diabetes
In conclusion, Ginger Vieira’s book, Exercise with Type 1 Diabetes (affiliate link), is a must-read for anyone with diabetes who wants to incorporate exercise into their daily routine.
Ginger’s expertise and personal experiences make this book a valuable resource for understanding the impact of exercise on blood sugar levels and managing diabetes effectively.
With practical tips and a supportive approach, Ginger empowers readers to take control of their health and enjoy the benefits of exercise. Don’t miss out on this concise and informative guide! ...
Source: Scott's Diabetes Blog - December 20, 2023 Category: Endocrinology Authors: Scott K. Johnson Tags: Blog Posts Source Type: blogs
Fight Aging! Newsletter, December 4th 2023
This study produced a great deal of data that continues to be mined for insights into human aging and effects of calorie restriction in a long-lived species such as our own, to contrast with the sizable effects on health and longevity in short-lived species such as mice.
In particular, and the topic for today, cellular senescence and its role in degenerative aging has garnered far greater interest in the research community in the years since the CALERIE study took place. Thus in today's open access paper, scientists examine CALERIE study data to find evidence for calorie restriction to reduce the burden of cellular ...
Source: Fight Aging! - December 3, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Arguing for SGLT2 Inhibitors to be Senomorphic Drugs
The incentives placed upon medical development ensure that far too much attention is given to ways in which established, existing drugs can be reused in other contexts, even given marginal effect sizes. It is much cheaper to repurpose an existing drug to a marginal new use than it is to build an actually effective new drug. To the extent that aging becomes a popular target for drug development, and one might argue that this is in the process of happening, every existing drug is going to be scrutinized in this context. Anti-diabetic drugs in particular seem to receive a lot of attention for potential marginal ability to slo...
Source: Fight Aging! - November 29, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Assessing Pentadecanoic Acid In Vitro
The work on pentadecanoic acid noted here is interesting, but should be taken with a grain of salt given that it is performed in vitro. In general, one should expect any given set of mechanisms in the cell to be associated with many different means of manipulation. It is interesting to see a fatty acid capable of touching on the same mechanisms as rapamycin, but remember that the ability to influence the same mechanistic targets does not necessarily translate to the same ability to produce a modest slowing of aging in animal studies. So the usual advice stands here, to wait for the animal studies before getting too excited...
Source: Fight Aging! - November 22, 2023 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, November 20th 2023
In this study, we attempted to further explain the role, exact mechanism and target of ICA in treating AD from the ferroptosis perspective. We found that ICA could improve the neurobehavioral, memory, and motor abilities of AD mice. It could lower the ferroptosis level and enhance the resistance to oxidative stress. After inhibition of MDM2, ICA could no longer improve the cognitive ability of AD mice, nor could it further inhibit ferroptosis. Network pharmacological analysis revealed that MDM2 might be the target of ICA action.
« Back to Top
Particulate Air Pollution and Its Effects on the Mechan...
Source: Fight Aging! - November 19, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
The Slow Spread of Off-Label Use for Treatments Shown to Target Mechanisms of Aging
A small number of low-cost and generic drugs have extensive human use and safety data, but also a sizable, compelling body of animal study evidence to suggest a likely modest slowing of aging, e.g. rapamycin, or that demonstrates the ability to target a mechanism of aging to reverse age-related disease, e.g. the dasatinib and quercetin, shown to selectively destroy senescent cells. In the US any drug approved for a given use can also be used off-label to treat other conditions. In principle the drug can be prescribed by any physician in this way. This is legal, though tends to require a slow bootstrapping process of educat...
Source: Fight Aging! - November 14, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, September 25th 2023
In conclusion, this individual patient data meta-analysis of longitudinal cohort studies found that antihypertensive use was associated with decreased dementia risk compared with individuals with untreated hypertension through all ages in late life. Individuals with treated hypertension had no increased risk of dementia compared with healthy controls.
« Back to Top
Results from Human Clinical Trials Do Not Support Metformin as a Longevity Drug
https://www.fightaging.org/archives/2023/09/results-from-human-clinical-trials-do-not-support-metformin-as-a-longevity-drug/
The SENS Research Fou...
Source: Fight Aging! - September 24, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Results from Human Clinical Trials Do Not Support Metformin as a Longevity Drug
The SENS Research Foundation staff have carried out the public service of extensively discussing and dismantling the evidence commonly cited in support of metformin as a way to modestly slow aging, showing that said evidence is problematic, to say the least. Metformin might make life modestly better for diabetics, but it doesn't slow aging. This view of the human data matches the poor quality of the animal model data, in which metformin makes a poor showing in comparison to the robust data for a modest slowing of aging that is produced by the use of, say, mTOR inhibitors, or the practice of calorie restriction.
Rega...
Source: Fight Aging! - September 21, 2023 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Fight Aging! Newsletter, September 11th 2023
This article reviews the current regulatory role of miR-7 in inflammation and related diseases, including viral infection, autoimmune hepatitis, inflammatory bowel disease, and encephalitis. It expounds on the molecular mechanism by which miR-7 regulates the occurrence of inflammatory diseases. Finally, the existing problems and future development directions of miR-7-based intervention on inflammation and related diseases are discussed to provide new references and help strengthen the understanding of the pathogenesis of inflammation and related diseases, as well as the development of new strategies for clinical interventi...
Source: Fight Aging! - September 10, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A High Level Popular Science View of the Longevity Industry
The article I'll point out today is an entirely unremarkable, high level tour of the most discussed, most notable portions of the longevity industry and related research efforts. Twenty years ago, we'd all have been delighted to see the media both noticing translational aging research at all, and then actually taking seriously the prospect of treating aging as a medical condition. We've come a long way to now see summary discussions of work on the treatment of aging as business as usual, not really worth mentioning. Still, articles like this miss near all of the really interesting projects, and that is the way of high leve...
Source: Fight Aging! - September 5, 2023 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
Fight Aging! Newsletter, September 4th 2023
In conclusion, although the contribution of CRF to GrimAgeAccel and FitAgeAccel is relatively low compared to lifestyle-related factors such as smoking, the results suggest that the maintenance of CRF is associated with delayed biological ageing in older men.
« Back to Top
Release of Acetylcholine is Necessary for the Aging Brain to Compensate for a Lack of Neurogenesis
https://www.fightaging.org/archives/2023/09/release-of-acetylcholine-is-necessary-for-the-aging-brain-to-compensate-for-a-lack-of-neurogenesis/
Neurogenesis is the process by which new neurons are created by neural stem c...
Source: Fight Aging! - September 3, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A Perspective on the Coming Regulatory Shift to Approval of Drugs to Treat Aging
At some point, regulatory bodies that oversee the development of new medicine will accept that therapies can target causative mechanisms of aging in order to slow or reverse the progression of aging, and that there are viable ways to assess new treatments that treat aging. There is growing pressure from the academic community and longevity-focused biotech industry for the ability to run clinical trials to treat aging, rather than to treat one specific age-related disease.
While inevitable, this change will take some years to come to pass, and likely require greater consensus in the research community on reasonable a...
Source: Fight Aging! - August 29, 2023 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
